UNLABELLED: The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. OBJECTIVE: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz ) registry is a non-interventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid records were entered into the database. Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data on monitoring and assessment of RCC targeted therapy on a national level.

Department of Complex Oncology Care Masaryk Memorial Cancer Institute Žlutý kopec 7 656 53 Brno Czech Republic

Zobrazit více v PubMed

Klin Onkol. 2010;23(5):311-24 PubMed

Lancet. 2007 Dec 22;370(9605):2103-11 PubMed

J Clin Oncol. 2008 Aug 1;26(22):3743-8 PubMed

Cancer. 2010 Dec 1;116(23):5383-90 PubMed

Onkologie. 2011;34(6):310-4 PubMed

N Engl J Med. 2007 Jan 11;356(2):115-24 PubMed

Urology. 2010 Aug;76(2):430-4 PubMed

N Engl J Med. 2007 May 31;356(22):2271-81 PubMed

Eur Urol. 2011 Dec;60(6):1163-70 PubMed

N Engl J Med. 2007 Jan 11;356(2):125-34 PubMed

J Am Med Inform Assoc. 1998 Mar-Apr;5(2):139-51 PubMed

Ann Oncol. 2012 Feb;23(2):395-401 PubMed

Ann Oncol. 2012 Jun;23(6):1549-55 PubMed

Cancer. 2010 Sep 15;116(18):4256-65 PubMed

BJU Int. 2011 Nov;108(10):1556-63 PubMed

Br J Cancer. 2011 Nov 22;105(11):1635-9 PubMed

Eur Urol. 2010 Dec;58(6):906-11 PubMed

Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry